Geron Corp (GERN)
3.885
+0.02
(+0.65%)
USD |
NASDAQ |
May 08, 11:12
Geron Enterprise Value: 1.929B for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 07, 2024 | 1.929B |
| May 06, 2024 | 1.852B |
| May 03, 2024 | 1.971B |
| May 02, 2024 | 1.983B |
| May 01, 2024 | 2.060B |
| April 30, 2024 | 1.971B |
| April 29, 2024 | 2.095B |
| April 26, 2024 | 1.888B |
| April 25, 2024 | 1.744B |
| April 24, 2024 | 1.756B |
| April 23, 2024 | 1.709B |
| April 22, 2024 | 1.845B |
| April 19, 2024 | 1.821B |
| April 18, 2024 | 1.845B |
| April 17, 2024 | 1.815B |
| April 16, 2024 | 1.756B |
| April 15, 2024 | 1.679B |
| April 12, 2024 | 1.792B |
| April 11, 2024 | 1.868B |
| April 10, 2024 | 1.673B |
| April 09, 2024 | 1.667B |
| April 08, 2024 | 1.608B |
| April 05, 2024 | 1.602B |
| April 04, 2024 | 1.537B |
| April 03, 2024 | 1.537B |
| Date | Value |
|---|---|
| April 02, 2024 | 1.472B |
| April 01, 2024 | 1.514B |
| March 31, 2024 | 1.591B |
| March 28, 2024 | 1.692B |
| March 27, 2024 | 1.697B |
| March 26, 2024 | 1.692B |
| March 25, 2024 | 1.668B |
| March 22, 2024 | 1.697B |
| March 21, 2024 | 1.709B |
| March 20, 2024 | 1.629B |
| March 19, 2024 | 1.531B |
| March 18, 2024 | 1.485B |
| March 15, 2024 | 1.586B |
| March 14, 2024 | 705.27M |
| March 13, 2024 | 705.27M |
| March 12, 2024 | 776.37M |
| March 11, 2024 | 916.95M |
| March 08, 2024 | 977.02M |
| March 07, 2024 | 895.11M |
| March 06, 2024 | 895.11M |
| March 05, 2024 | 889.64M |
| March 04, 2024 | 884.18M |
| March 01, 2024 | 982.48M |
| February 29, 2024 | 840.36M |
| February 28, 2024 | 813.06M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
38.44M
Minimum
Mar 18 2020
2.095B
Maximum
Apr 29 2024
529.76M
Average
370.52M
Median
Enterprise Value Benchmarks
| Madrigal Pharmaceuticals Inc | 3.817B |
| SELLAS Life Sciences Group Inc | 71.74M |
| Johnson & Johnson | 365.34B |
| Pfizer Inc | 215.68B |
| Immuneering Corp | -39.41M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -55.39M |
| Revenue (Quarterly) | 0.304M |
| Total Expenses (Quarterly) | 56.44M |
| EPS Diluted (Quarterly) | -0.09 |
| Profit Margin (Quarterly) | -18.22K% |
| Earnings Yield | -9.01% |
| Normalized Earnings Yield | -9.009 |